Summary
46 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: ¥2.24B against ¥432.9M.
- Out of every 100 CNY of revenue, 12 CNY is left as free cash.
What to watch
- Operating profit does not even cover the interest on its debt.
- It pays out more in dividends than it earns: 162% of profit.
- The share price is above the Bulios Fair Price.
- It earns only 0.2 CNY a year on every 100 CNY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 57.4 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 5.4% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 CNY of revenue goes
- Cost of sales 52 CNY
- Research and development 13 CNY
- Sales and administration 85 CNY
- Taxes and other -4.4 CNY
- Net profit 4.8 CNY
Net profit, industry median (Medical - Instruments & Supplies) 8.2 CNY
Out of every 100 CNY of revenue, 4.8 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.6 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.82%
- Paid out of profit
- 162%
You receive ¥0.85 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail